bluuebunny/crossref_metadata_2025 huggingface dataset:
Sup. Figure 9: Foretinib treatment had no remarkable anti-angiogenic effect in the liver metastasis model or brain metastasis-mimicking model. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Authors: Nishiyama Akihiro , Yamada Tadaaki , Kita Kenji , Wang Rong , Arai Sachiko , Fukuda Koji , Tanimoto Azusa , Takeuchi Shinji , Tange Shoichiro , Tajima Atsushi , Furuya Noritaka , Kinoshita Takayoshi , Yano Seiji
Published: April 2023

Tumor tissues obtained in the liver metastasis model (Fig. 5) and brain metastasis-mimicking model (Fig. 6) were assessed for microvessel density. Sections of formalin-fixed and paraffin-embedded tissues were stained with anti-mouse CD31 antibody and evaluated by a standard IHC assay. (A) Representative pictures are shown. Bars indicate 100 Âµm. (B) The number of CD31-positive cells in the high-power field (200Ã-) was quantified. Data shown are mean {plus minus} SD of three independent areas. No significant difference was observed among the control, entrectinib-treated, and foretinib-treated groups.
Movie S1 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Authors: Zhang Gao , Wu Lawrence W. , Mender Ilgen , Barzily-Rokni Michal , Hammond Marc R. , Ope Omotayo , Cheng Chaoran , Vasilopoulos Themistoklis , Randell Sergio , Sadek Norah , Beroard Aurelie , Xiao Min , Tian Tian , Tan Jiufeng , Saeed Umar , Sugarman Eric , Krepler Clemens , Brafford Patricia , Sproesser Katrin , Murugan Sengottuvelan , Somasundaram Rajasekharan , Garman Bradley , Wubbenhorst Bradley , Woo Jonathan , Yin Xiangfan , Liu Qin , Frederick Dennie T. , Miao Benchun , Xu Wei , Karakousis Giorgos C. , Xu Xiaowei , Schuchter Lynn M. , Mitchell Tara C. , Kwong Lawrence N. , Amaravadi Ravi K. , Lu Yiling , Boland Genevieve M. , Wei Zhi , Nathanson Katherine , Herbig Utz , Mills Gordon B. , Flaherty Keith T. , Herlyn Meenhard , Shay Jerry W.
Published: April 2023

Time-lapse imaging of A375(Fucci2) cells treated with the control.
Supplemental tables from Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Authors: Loree Jonathan M. , Pereira Allan A.L. , Lam Michael , Willauer Alexandra N. , Raghav Kanwal , Dasari Arvind , Morris Van. K , Advani Shailesh , Menter David G. , Eng Cathy , Shaw Kenna , Broaddus Russell , Routbort Mark J. , Liu Yusha , Morris Jeffrey S. , Luthra Rajyalakshmi , Meric-Bernstam Funda , Overman Michael J. , Maru Dipen , Kopetz Scott
Published: April 2023

Supplemental Table 1. Mutation and Consensus Molecular Subtype (CMS) profile of patients with colorectal cancer classified by tumor site. Supplemental Table 2. Mutation profile of patients with stage IV colorectal cancer stratified by tumor side and site of biopsy. Supplementary Table 3. Summary of univariate and multivariate models used to compare overall survival in metastatic colorectal cancer based on primary tumor location.
Supplemental legend from Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Authors: Loree Jonathan M. , Pereira Allan A.L. , Lam Michael , Willauer Alexandra N. , Raghav Kanwal , Dasari Arvind , Morris Van. K , Advani Shailesh , Menter David G. , Eng Cathy , Shaw Kenna , Broaddus Russell , Routbort Mark J. , Liu Yusha , Morris Jeffrey S. , Luthra Rajyalakshmi , Meric-Bernstam Funda , Overman Michael J. , Maru Dipen , Kopetz Scott
Published: April 2023

Supplemental legend
Supplementary Figure 1 from Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors
Authors: Sherborne Amy L. , Lavergne Vincent , Yu Katharine , Lee Leah , Davidson Philip R. , Mazor Tali , Smirnoff Ivan V. , Horvai Andrew E. , Loh Mignon , DuBois Steven G. , Goldsby Robert E. , Neglia Joseph P. , Hammond Sue , Robison Leslie L. , Wustrack Rosanna , Costello Joseph F. , Nakamura Alice O. , Shannon Kevin M. , Bhatia Smita , Nakamura Jean L.
Published: April 2023

Supplementary Figure 1: Radiotherapy-induced sarcomas in pediatric cancer survivors Radiation dosimetry, imaging and histology are shown.
Supplemental tables and figures from Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer
Authors: Hill Andrew G. , Findlay Michael P. , Burge Matthew E. , Jackson Christopher , Alfonso Pilar Garcia , Samuel Leslie , Ganju Vinod , Karthaus Meinolf , Amatu Alessio , Jeffery Mark , Bartolomeo Maria Di , Bridgewater John , Coveler Andrew L. , Hidalgo Manuel , Kapp Amy V. , Sufan Roxana I. , McCall Bruce B. , Hanley William D. , Penuel Elicia M. , Pirzkall Andrea , Tabernero Josep
Published: April 2023

Supplemental tables and figures Supplemental Table 1. Study drug exposure. Supplemental Table 2. Select AEs at relatively high frequency led to disproportionately more frequent irinotecan/5-FU dose changes (reduced, interrupted, or withdrawn) on the duligotuzumab arm. Supplemental Figure 1. CONSORT patient flow diagram
Supplementary Data from Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy
Authors: Wang Qiongyao , Zeng Fanrui , Sun Yanqin , Qiu Qianqian , Zhang Jian , Huang Weimei , Huang Jie , Huang Xiaomin , Guo Linlang
Published: April 2023

Supplementary Data of Figure.S1-S4 and Table S1-S5 Table S1. The expression of PFKFB4 and Etk and their relationships with the clinicopathological characteristics in SCLC patients Table S2. Univariate and multivariate analyses of potential prognostic factors associated with overall survival of SCLC patients Table S3. The clinicopathological characteristics of the patient that donated SCLC specimen to perform PDX experiment. Table S4. Sequences of siRNA. Table S5. qRT-PCR primers
Supplementary Figure Legends, Supplementary Figures 1-8, Supplementary References, Supplemental Information (1) on treatment protocols from Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma
Authors: Chicard Mathieu , Colmet-Daage Leo , Clement Nathalie , Danzon Adrien , Bohec Mylène , Bernard Virginie , Baulande Sylvain , Bellini Angela , Deveau Paul , Pierron Gaëlle , Lapouble Eve , Janoueix-Lerosey Isabelle , Peuchmaur Michel , Corradini Nadège , Defachelles Anne Sophie , Valteau-Couanet Dominique , Michon Jean , Combaret Valérie , Delattre Olivier , Schleiermacher Gudrun
Published: April 2023

Figure S1 : Sequencing plan; Figure S2: Examples of a high resolution electrophoresis profiles of cfDNA; Figure S3; Mean Coverage observed between Tumor, Germline and cfDNA sequencing; Figure S4: Estimation of the sensitivity of WES and targeted sequencing of cfDNA; Figure S5: CtDNA fraction in total cfDNA at diagnosis (n=19 patients) and at the 2nd timepoint (CR/PR, n=8 patients); Figure S6: Scatterplot of MAFs between WES on primary tumor and cfDNA (A) and WES and TargetSeq (B); Figure S7: Clonal Evolution detected with Target Sequencing; Figure S8: Example of resurgence of MAFs (Case 6) which will be followed by a relapse.
Supplemental Figure 5 from Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor
Authors: Vitiello Gerardo A. , Medina Benjamin D. , Zeng Shan , Bowler Timothy G. , Zhang Jennifer Q. , Loo Jennifer K. , Param Nesteene J. , Liu Mengyuan , Moral Alec J. , Zhao Julia N. , Rossi Ferdinand , Antonescu Cristina R. , Balachandran Vinod P. , Cross Justin R. , DeMatteo Ronald P.
Published: April 2023

HIF1a mRNA expression in KitV558del/+ mice and 72h cell viability assay of GIST-T1 cells treated with ferric iron chloride + VLX600
Supplementary Table 2 from Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study
Authors: Nieuweboer Annemieke J.M. , de Graan Anne-Joy M. , Hamberg Paul , Bins Sander , van Soest Robert J. , van Alphen Robbert J. , Bergman Andries M. , Beeker Aart , van Halteren Henk , ten Tije Albert J. , Zuetenhorst Hanneke , van der Meer Nelly , Chitu Dana , de Wit Ronald , Mathijssen Ron H.J.
Published: April 2023

Reasons of inevaluability
Supplemental Figure 2 from Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor
Authors: Vitiello Gerardo A. , Medina Benjamin D. , Zeng Shan , Bowler Timothy G. , Zhang Jennifer Q. , Loo Jennifer K. , Param Nesteene J. , Liu Mengyuan , Moral Alec J. , Zhao Julia N. , Rossi Ferdinand , Antonescu Cristina R. , Balachandran Vinod P. , Cross Justin R. , DeMatteo Ronald P.
Published: April 2023

72h cell viability assays of GIST cell lines treated with VLX600
Supplementary data from lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study
Authors: Martini Paolo , Paracchini Lara , Caratti Giulia , Mello-Grand Maurizia , Fruscio Robert , Beltrame Luca , Calura Enrica , Sales Gabriele , Ravaggi Antonella , Bignotti Eliana , Odicino Franco E. , Sartori Enrico , Perego Patrizia , Katsaros Dionyssios , Craparotta Ilaria , Chiorino Giovanna , Cagnin Stefano , Mannarino Laura , Ceppi Lorenzo , Mangioni Costantino , Ghimenti Chiara , D'Incalci Maurizio , Marchini Sergio , Romualdi Chiara
Published: April 2023

Supplementary data, material and results. Figure S1.1. Overall analysis schema Table S1.1 REMARK form. Figure S1.2 a) Kaplan Meier curves of patients divided by tumor grades (OS and PFS model). The table below summarizes the models used. Figure S1.2 b) Kaplan Meier curves of patients divided in patients who received chemotherapy (Yes) and patients who did not undergo chemotherapy (No). Figure S1.2 c) Kaplan Meier curves of patients divided in FIGO substages. The table below summarizes the models used.
Table S5 from Long Noncoding RNA LINC01234 Functions as a Competing Endogenous RNA to Regulate CBFB Expression by Sponging miR-204-5p in Gastric Cancer
Authors: Chen Xin , Chen Zhenyao , Yu Shanxun , Nie Fengqi , Yan Shuai , Ma Pei , Chen Qinnan , Wei Chenchen , Fu Hangjiang , Xu Tianwei , Ren Shengnan , Sun Ming , Wang Zhaoxia
Published: April 2023

Primers, siRNA, shRNA, and antibodies information
Supplementary Table 2 from Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases
Authors: Chan Nancy , Willis Amy , Kornhauser Naomi , Ward Maureen M. , Lee Sharrell B. , Nackos Eleni , Seo Bo Ri , Chuang Ellen , Cigler Tessa , Moore Anne , Donovan Diana , Vallee Cobham Marta , Fitzpatrick Veronica , Schneider Sarah , Wiener Alysia , Guillaume-Abraham Jessica , Aljom Elnaz , Zelkowitz Richard , Warren J. David , Lane Maureen E. , Fischbach Claudia , Mittal Vivek , Vahdat Linda
Published: April 2023

This is the demographics table containing detailed baseline patient characteristics listed for each of the 75 patients. The data is de-identified.
Suppl. Table 1 from Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Authors: Theodoraki Marie-Nicole , Yerneni Saigopalakrishna S. , Hoffmann Thomas K. , Gooding William E. , Whiteside Theresa L.
Published: April 2023

Percent CD63+ exosomes on beads
Suppl. Figure 4 from Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Authors: Theodoraki Marie-Nicole , Yerneni Saigopalakrishna S. , Hoffmann Thomas K. , Gooding William E. , Whiteside Theresa L.
Published: April 2023

Soluble PD-L1 levels and clinicopathological patient profiles
Suppl. Figure 1 from Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Authors: Theodoraki Marie-Nicole , Yerneni Saigopalakrishna S. , Hoffmann Thomas K. , Gooding William E. , Whiteside Theresa L.
Published: April 2023

Presentation of exosome capture and flow cytometry
Table S2 from Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
Authors: Neven Patrick , Jongen Lynn , Lintermans Anneleen , Van Asten Kathleen , Blomme Chantal , Lambrechts Diether , Poppe An , Wildiers Hans , Dieudonné Anne-Sophie , Brouckaert Olivier , Decloedt Jan , Berteloot Patrick , Verhoeven Didier , Joerger Markus , Vuylsteke Peter , Wynendaele Wim , Casteels Minne , Van Huffel Sabine , Lybaert Willem , Van Ginderachter Johan , Paridaens Robert , Vergote Ignace , Dezentjé Vincent Olaf , Van Calster Ben , Guchelaar Henk-Jan
Published: April 2023

Results of ordinal regression models of the questionnaire items on endoxifen level after multiple imputation.
Supplementary Table 3 from A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy
Authors: Yang Qi , Zhang Meng-Xia , Zou Xiong , Liu You-Ping , You Rui , Yu Tao , Jiang Rou , Zhang Yi-Nuan , Cao Jing-Yu , Hong Ming-Huang , Liu Qing , Guo Ling , Kang Tie-Bang , Zhu Xiao-Feng , Chen Ming-Yuan
Published: April 2023

Multivariate analysis with the Cox proportional hazards model for the distant metastasis-free survival of NPC patients.
FigureS7 from Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia
Authors: Di Marcantonio Daniela , Martinez Esteban , Sidoli Simone , Vadaketh Jessica , Nieborowska-Skorska Margaret , Gupta Anushk , Meadows Jake M. , Ferraro Francesca , Masselli Elena , Challen Grant A. , Milsom Michael D. , Scholl Claudia , Fröhling Stefan , Balachandran Siddharth , Skorski Tomasz , Garcia Benjamin A. , Mirandola Prisco , Gobbi Giuliana , Garzon Ramiro , Vitale Marco , Sykes Stephen M.
Published: April 2023

Supplemental Figure 7. (A-D) OCI-AML3 cells were transduced with lentiviruses expressing CTRL shRNA or SOD2 shRNA and analyzed for: (A) Western blot analysis 4 days after transduction with the indicated antibodies. (B) MitoSOX and Annexin V staining by flow cytometry, 4 days after transduction. The bar graph shows the MitoSOX median fluorescence intensity (MFI) of live (Annexin V-) cells and data is expressed as mean {plus minus} SD of three independent experiments. (C) Cell growth every 2 days by MTS analysis. Data represents the mean {plus minus} SD of three independent replicates. (D) Annexin V staining 5 days after transduction. Data represents the mean {plus minus} SD of three independent replicates. (E) Bar graph representing the number of colonies formed by mouse MLL-AF9 leukemia cells transduced with CTRL shRNA, Sod2 shRNA_1 and Sod2 shRNA_2 in methylcellulose culture. Data is expressed as mean {plus minus} SD of three independent replicates. (*p{less than or equal to}0.05, **p{less than or equal to}0.01; ****p<0.0001). (F) Heatmap analysis displaying the expression of redox-regulatory proteins that were differentially expressed between CTRL shRNA, PKCÎµ shRNA_1 or PKCÎµ shRNA_2 transduced OCI-AML3 cells (4 days after transduction). The proteins differences displayed were not statistically significant.
Supplementary Figure 3 from Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
Authors: Qu Fangfang , Xie Wanling , Nakabayashi Mari , Zhang Haitao , Jeong Seong Ho , Wang Xiaodong , Komura Kazumasa , Sweeney Christopher J. , Sartor Oliver , Lee Gwo-Shu Mary , Kantoff Philip W.
Published: April 2023

Separation of positive and negative droplets in ddPCR assays of AR-V7, AR-FL and PSA genes expression.
Supplement figure 5 from Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury
Authors: Yarana Chontida , Carroll Dustin , Chen Jing , Chaiswing Luksana , Zhao Yanming , Noel Teresa , Alstott Michael , Bae Younsoo , Dressler Emily V. , Moscow Jeffrey A. , Butterfield D. Allan , Zhu Haining , St. Clair Daret K.
Published: April 2023

Western blots display PYGB, PYGM, and PYGL expression. A. EVs from mice treated with saline or DOX. B. PYGB in EVs and heart tissues from wild-type or MnSOD Tg mice treated with saline or DOX. C. PYGB in EVs and heart tissues from mice treated with MnP or DRZ prior to saline or DOX treatment.
Supplement Table 1 from Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury
Authors: Yarana Chontida , Carroll Dustin , Chen Jing , Chaiswing Luksana , Zhao Yanming , Noel Teresa , Alstott Michael , Bae Younsoo , Dressler Emily V. , Moscow Jeffrey A. , Butterfield D. Allan , Zhu Haining , St. Clair Daret K.
Published: April 2023

Proteins identified in both SAL_EVs and DOX_EVs
Figure S1 from Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus
Authors: Gavvovidis Ioannis , Leisegang Matthias , Willimsky Gerald , Miller Natalie , Nghiem Paul , Blankenstein Thomas
Published: April 2023

Transduction of WaGa cells with MP71 vector encoding for trimeric epitope
Supplement Figure 1 from Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury
Authors: Yarana Chontida , Carroll Dustin , Chen Jing , Chaiswing Luksana , Zhao Yanming , Noel Teresa , Alstott Michael , Bae Younsoo , Dressler Emily V. , Moscow Jeffrey A. , Butterfield D. Allan , Zhu Haining , St. Clair Daret K.
Published: April 2023

Sucrose gradient isolation process for proteomics analysis. A. Diagram showing the process of EV isolation by sucrose gradient method. B. Western blots of EV markers, CD63 and CD81 of sucrose gradient fraction 1 to 5 (from the top to the bottom). C. EV verification of isolation process by electron microscopy (X49,000).
Supplementary Table 1 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer
Authors: McCoach Caroline E. , Le Anh T. , Gowan Katherine , Jones Kenneth , Schubert Laura , Doak Andrea , Estrada-Bernal Adriana , Davies Kurtis D. , Merrick Daniel T. , Bunn Paul A. , Purcell W. Tom , Dziadziuszko Rafal , Varella-Garcia Marileila , Aisner Dara L. , Camidge D. Ross , Doebele Robert C.
Published: April 2023

Custom capture-based NGS panel of 48 genes
Supplementary legend from NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Authors: Griffiths Elizabeth A. , Srivastava Pragya , Matsuzaki Junko , Brumberger Zachary , Wang Eunice S. , Kocent Justin , Miller Austin , Roloff Gregory W. , Wong Hong Yuen , Paluch Benjamin E. , Lutgen-Dunckley Linda G. , Martens Brandon L. , Odunsi Kunle , Karpf Adam R. , Hourigan Christopher S. , Nemeth Michael J.
Published: April 2023

Supplementary legend
Supplemental tables from NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Authors: Griffiths Elizabeth A. , Srivastava Pragya , Matsuzaki Junko , Brumberger Zachary , Wang Eunice S. , Kocent Justin , Miller Austin , Roloff Gregory W. , Wong Hong Yuen , Paluch Benjamin E. , Lutgen-Dunckley Linda G. , Martens Brandon L. , Odunsi Kunle , Karpf Adam R. , Hourigan Christopher S. , Nemeth Michael J.
Published: April 2023

Supplemental Table 1. Clinical characteristics of enrolled patients. Supplemental Table 2. Antibodies used in flow cytometry experiments Supplemental Table 3. Primers and Taqman probes used in quantitative pyrosequencing and RT-PCR experiments. Supplemental Table 4. Patient safety data. Supplemental Table 5. Molecular profile and therapeutic response. Supplemental Table 6. Antibody titers for common vaccine targets.
Figure S5 from NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
Authors: Griffiths Elizabeth A. , Srivastava Pragya , Matsuzaki Junko , Brumberger Zachary , Wang Eunice S. , Kocent Justin , Miller Austin , Roloff Gregory W. , Wong Hong Yuen , Paluch Benjamin E. , Lutgen-Dunckley Linda G. , Martens Brandon L. , Odunsi Kunle , Karpf Adam R. , Hourigan Christopher S. , Nemeth Michael J.
Published: April 2023

Supplemental Figure 5. Expression of DC associated cell surface proteins in CD141Hi cells post-decitabine.
PROTECT Study Investigators from Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
Authors: Sternberg Cora N. , Donskov Frede , Haas Naomi B. , Doehn Christian , Russo Paul , Elmeliegy Mohamed , Baneyx Guillaume , Banerjee Hiya , Aimone Paola , Motzer Robert J.
Published: April 2023

List of PROTECT Study investigators
IRAK1 and/or IRAK4 knockdown sensitizes PDAC cells to chemotherapeutics. from Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
Authors: Zhang Daoxiang , Li Lin , Jiang Hongmei , Knolhoff Brett L. , Lockhart Albert C. , Wang-Gillam Andrea , DeNardo David G. , Ruzinova Marianna B. , Lim Kian-Huat
Published: April 2023

Supplementary Table 1. IRAK1 and/or IRAK4 knockdown sensitizes PDAC cells to chemotherapeutics.
Table S2 from Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis
Authors: Liu Liang , Yang Lin , Yan Wei , Zhai Jing , Pizzo Donald P. , Chu Peiguo , Chin Andrew R. , Shen Meng , Dong Chuan , Ruan Xianhui , Ren Xiubao , Somlo George , Wang Shizhen Emily
Published: April 2023

Table S2 shows sequences of the primers used in RT-qPCR
Table S1 from Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis
Authors: Liu Liang , Yang Lin , Yan Wei , Zhai Jing , Pizzo Donald P. , Chu Peiguo , Chin Andrew R. , Shen Meng , Dong Chuan , Ruan Xianhui , Ren Xiubao , Somlo George , Wang Shizhen Emily
Published: April 2023

Table S1 shows the clinical data of human specimens
Figure S1 from Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis
Authors: Liu Liang , Yang Lin , Yan Wei , Zhai Jing , Pizzo Donald P. , Chu Peiguo , Chin Andrew R. , Shen Meng , Dong Chuan , Ruan Xianhui , Ren Xiubao , Somlo George , Wang Shizhen Emily
Published: April 2023

Figure S1 shows that post-NT sera from BC patients stimulate a CSC phenotype and contain elevated levels of MCPs
Supplementary Materials from Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials
Authors: Chen Yu-Pei , Tang Ling-Long , Yang Qi , Poh Sharon-Shuxian , Hui Edwin P. , Chan Anthony T.C. , Ong Whee-Sze , Tan Terence , Wee Joseph , Li Wen-Fei , Chen Lei , Ma Brigette B.Y. , Tong Macy , Tan Sze-Huey , Cheah Shie-Lee , Fong Kam-Weng , Sommat Kiattisa , Soong Yoke Lim , Guo Ying , Lin Ai-Hua , Sun Ying , Hong Ming-Huang , Cao Su-Mei , Chen Ming-Yuan , Ma Jun
Published: April 2023

Supplementary materials including supplementary figures and tables Supplementary Figure S1. Flowchart of randomized controlled trial selection. AC, adjuvant chemotherapy; CCRT, concurrent chemoradiotherapy; GZ, Guangzhou; HeCOG, Hellenic Cooperative Oncology Group; IC, induction chemotherapy; NCCS, National Cancer Centre Singapore; NPC, nasopharyngeal carcinoma; PWH, Prince of Wales Hospital; RCT, randomized controlled trial Supplementary Figure S2. Forest plots for (A) progression-free survival and (B) overall survival. The estimated hazard ratio (HR) for each individual trial is indicated by the center of the square and the horizontal line gives the 95% confidence interval (CI). The closed diamonds show the overall HR and 95% CI. HR < 1 and 95% CI excluding 1 indicate improved survival for the experimental versus control arm. A fixed effect model was used. CCRT, concurrent chemoradiotherapy; GZ, Guangzhou; HeCOG, Hellenic Cooperative Oncology Group; IC, induction chemotherapy; NCCS, National Cancer Centre Singapore; NPC, nasopharyngeal carcinoma; O-E, observed minus expected deaths or events; PWH, Prince of Wales Hospital. Supplementary Figure S3. Multiple treatment comparison network. Each treatment area is proportional to the cumulative number of patients (in parentheses). Solid lines between treatments represent direct comparisons. AC, adjuvant chemotherapy; CCRT, concurrent chemoradiotherapy; CEP, cisplatin, epirubicin and paclitaxel; GCP, gemcitabine, carboplatin and paclitaxel; IC, induction chemotherapy; PF, cisplatin and fluorouracil; PX, cisplatin and capecitabine; TP, docetaxel and cisplatin; TPF, TP and fluorouracil. Supplementary Table S1. Description of the Two Trials Included in the Supplementary Analysis Supplementary Table S2. Description of Patient Characteristics Supplementary Table S3. Disease Status and Pattern of FailureSupplementary Table S4. Compliance with Induction Chemotherapy and Concurrent Chemoradiotherapy Supplementary Table S5. Summary of Major Grade 3-4 Adverse Events*
Supplementary Table S1: Searches on PubMed using keyword(s) and DICER1 from DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies
Authors: Schultz Kris Ann P. , Williams Gretchen M. , Kamihara Junne , Stewart Douglas R. , Harris Anne K. , Bauer Andrew J. , Turner Joyce , Shah Rachana , Schneider Katherine , Schneider Kami Wolfe , Carr Ann Garrity , Harney Laura A. , Baldinger Shari , Frazier A. Lindsay , Orbach Daniel , Schneider Dominik T. , Malkin David , Dehner Louis P. , Messinger Yoav H. , Hill D. Ashley
Published: April 2023

Searches on PubMed using keyword(s) and DICER1
Supplementary_Figures_S1-S6 from NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma
Authors: Weiss Tobias , Schneider Hannah , Silginer Manuela , Steinle Alexander , Pruschy Martin , Polić Bojan , Weller Michael , Roth Patrick
Published: April 2023

Revised Supplementary Figures
Supplementary Figure 1- from Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy
Authors: Shachar Shlomit Strulov , Deal Allison M. , Weinberg Marc , Nyrop Kirsten A. , Williams Grant R. , Nishijima Tomohiro F. , Benbow Julia M. , Muss Hyman B.
Published: April 2023

Selection of patients for the study
Supplementary information from Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma
Authors: Jin Yanli , Zhang Ping , Wang Yun , Jin Bei , Zhou Jingfeng , Zhang Jing , Pan Jingxuan
Published: April 2023

Supplementary information
Supplemental legend from Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement
Authors: Bellone Stefania , Buza Natalia , Choi Jungmin , Zammataro Luca , Gay Laurie , Elvin Julia , Rimm David L. , Liu Yuting , Ratner Elena S. , Schwartz Peter E. , Santin Alessandro D.
Published: April 2023

Supplemental legend
Figure S6 from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary Figure 6: ISTH1047 or ISTH0047 reduce glioma cell invasion.
Figure S4 from Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients
Authors: Drögemöller Britt I. , Brooks Beth , Critchley Carol , Monzon José G. , Wright Galen E.B. , Liu Geoffrey , Renouf Daniel J. , Kollmannsberger Christian K. , Bedard Philippe L. , Hayden Michael R. , Gelmon Karen A. , Carleton Bruce C. , Ross Colin J.D.
Published: April 2023

Figure S4 provides examples of audiogram configurations
Table S4 from Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Authors: Zhang Wei , Liu Bo , Wu Wenhui , Li Likun , Broom Bradley M. , Basourakos Spyridon P. , Korentzelos Dimitrios , Luan Yang , Wang Jianxiang , Yang Guang , Park Sanghee , Azad Abul Kalam , Cao Xuhong , Kim Jeri , Corn Paul G. , Logothetis Christopher J. , Aparicio Ana M. , Chinnaiyan Arul M. , Navone Nora , Troncoso Patricia , Thompson Timothy C.
Published: April 2023

Differential expression results and pathway distribution for common significant DDR-M genes in Beltran's and PDX RNAseq datasets
Supplemental Data from Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Authors: Li Megan , Mulkey Flora , Jiang Chen , O’Neil Bert H. , Schneider Bryan P. , Shen Fei , Friedman Paula N. , Momozawa Yukihide , Kubo Michiaki , Niedzwiecki Donna , Hochster Howard S. , Lenz Heinz-Josef , Atkins James N. , Rugo Hope S. , Halabi Susan , Kelly William Kevin , McLeod Howard L. , Innocenti Federico , Ratain Mark J. , Venook Alan P. , Owzar Kouros , Kroetz Deanna L.
Published: April 2023

Supplemental Methods, Tables and Figures Table S1. Analyzed candidate genes Table S2. Gene sets and pathways used for candidate gene selection Table S3. Quality of sequencing reads per sample Table S4. Post-QC quality per sample Table S5. Replication cohorts Table S6. Gene-based analysis of rare and low frequency variants (MAF < 0.03) in candidate genes Table S7. Characteristics of replication patient subgroups Figure S1. Candidate gene analysis workflow. Figure S2. Associations with bevacizumab-induced hypertension in the SLC29A1-HSP90AB1 region. Figure S3. Top SLC29A1-HSP90AB1 SNPs are in predicted transcriptionally active regions in human umbilical vein endothelial cells. Figure S4. Proportion of high-grade hypertension in replication cohorts stratified by variant allele carrier status. Figure S5. Dose-dependent effects of adenosine on cyclic AMP and nitric oxide levels. Figure S6. Effects of adenosine receptor blockade on cyclic AMP and nitric oxide levels in HUVEC. Figure S7. Effect of ENT1 inhibition on cyclic AMP levels. Figure S8. Effect of SLC29A1-overexpression on cyclic AMP levels in HUVEC. Figure S9. Linkage disequilibrium plot of SLC29A1-HSP90AB1 intergenic region.
Supplemental Tables S1 to S4 and Figures S1 to S5 including legends and footnotes from Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
Authors: Brant Roz , Sharpe Alan , Liptrot Tom , Dry Jonathan R. , Harrington Elizabeth A. , Barrett J. Carl , Whalley Nicky , Womack Christopher , Smith Paul , Hodgson Darren R.
Published: April 2023

Supplemental Table 1: Design of Affymetrix and NanoString probes Supplemental Table 2: Genes included in the NanoString Codeset, including genes up- and down-regulated by MEK, Cres and KRAS signatures, plus housekeeper genes Supplemental Table 3: Correlation between Affymetrix and NanoString data for Batch Comparison or New probes Supplemental Table 4: Pearson's correlation coefficients for MEK and Cres gene probes in NSCLC FFPET Supplemental Fig 1: The MEK signature is dynamic in lung cancer cell lines as demonstrated by MEK inhibition with selumetinib and siRNA mediated KRAS knockdown Supplemental Fig 2: Pearson's correlation coefficients for the most correlated MEK and Cres probes in NSCLC FFPET Supplemental Fig 3: NanoString gene expression range of MEK and CRes genes Supplemental Fig 4: Scatterplots showing correlations between MEK, Cres and RAS signatures Supplemental Fig 5: Pearson's correlations demonstrated a high agreement of MEK signature expression between gene probe batches
Supplementary Table S2 from A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
Authors: Berger Martin D. , Stintzing Sebastian , Heinemann Volker , Cao Shu , Yang Dongyun , Sunakawa Yu , Matsusaka Satoshi , Ning Yan , Okazaki Satoshi , Miyamoto Yuji , Suenaga Mitsukuni , Schirripa Marta , Hanna Diana L. , Soni Shivani , Puccini Alberto , Zhang Wu , Cremolini Chiara , Falcone Alfredo , Loupakis Fotios , Lenz Heinz-Josef
Published: April 2023

SNPs and clinical outcomes among patients with mCRC treated with first-line FOLFIRI/bevacizumab in FIRE-3 (discovery cohort)
Supplementary Table S1 from A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
Authors: Berger Martin D. , Stintzing Sebastian , Heinemann Volker , Cao Shu , Yang Dongyun , Sunakawa Yu , Matsusaka Satoshi , Ning Yan , Okazaki Satoshi , Miyamoto Yuji , Suenaga Mitsukuni , Schirripa Marta , Hanna Diana L. , Soni Shivani , Puccini Alberto , Zhang Wu , Cremolini Chiara , Falcone Alfredo , Loupakis Fotios , Lenz Heinz-Josef
Published: April 2023

Analyzed SNPs involved in vitamin D transport, metabolism and signaling. Overview on their functional significance and primer sequences
Figure S1 from Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
Authors: Camblin Adam J. , Pace Emily A. , Adams Sharlene , Curley Michael D. , Rimkunas Victoria , Nie Lin , Tan Gege , Bloom Troy , Iadevaia Sergio , Baum Jason , Minx Charlene , Czibere Akos , Louis Chrystal U. , Drummond Daryl C. , Nielsen Ulrik B. , Schoeberl Birgit , Pipas J. Marc , Straubinger Robert M. , Askoxylakis Vasileios , Lugovskoy Alexey A.
Published: April 2023

Supplemental Figure S1: IGF-1 and HRG induce strongest AKT phosphorylation in pancreatic cancer cells.
Figure S2 from 5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial
Authors: Maytin Edward V. , Anand Sanjay , Riha Margo , Lohser Sara , Tellez Alejandra , Ishak Rim , Karpinski Lauren , Sot Janine , Hu Bo , Denisyuk Anton , Davis Scott C. , Kyei Angela , Vidimos Allison
Published: April 2023

Western analyses of CPO levels in normal skin and UVB-induced AK-like lesions in mice
Figure S1 from 5-Fluorouracil Enhances Protoporphyrin IX Accumulation and Lesion Clearance during Photodynamic Therapy of Actinic Keratoses: A Mechanism-Based Clinical Trial
Authors: Maytin Edward V. , Anand Sanjay , Riha Margo , Lohser Sara , Tellez Alejandra , Ishak Rim , Karpinski Lauren , Sot Janine , Hu Bo , Denisyuk Anton , Davis Scott C. , Kyei Angela , Vidimos Allison
Published: April 2023

Western analyses of four heme synthetic enzymes in human AK lesions
Supplementary Figure 3 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
Authors: Slaney Clare Y. , von Scheidt Bianca , Davenport Alexander J. , Beavis Paul A. , Westwood Jennifer A. , Mardiana Sherly , Tscharke David C. , Ellis Sarah , Prince H. Miles , Trapani Joseph A. , Johnstone Ricky W. , Smyth Mark J. , Teng Michele W. , Ali Aesha , Yu Zhiya , Rosenberg Steven A. , Restifo Nicholas P. , Neeson Paul , Darcy Phillip K. , Kershaw Michael H.
Published: April 2023

CAR T cells lacking the pMEL TCR are less effective than CARaMEL T cells at inhibiting tumor growth.
Supplementary Figure and Table Legends from Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer
Authors: Gupta Santosh , Li Jing , Kemeny Gabor , Bitting Rhonda L. , Beaver Joshua , Somarelli Jason A. , Ware Kathryn E. , Gregory Simon , Armstrong Andrew J.
Published: April 2023

Supplementary Figure and Table Legends.
Supplemental Table 3 from Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma
Authors: Yang Qingshan , Chen Lisa S. , Ha Min Jin , Do Kim-Anh , Neelapu Sattva S. , Gandhi Varsha
Published: April 2023

Supplemental Table 3. Primary antibody information.
Supplementary Materials and Methods from A Novel HSP90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer
Authors: Gaponova Anna V. , Nikonova Anna S. , Deneka Alexander Y. , Kopp Meghan C. , Kudinov Alexander E. , Skobeleva Natalia , Khazak Vladimir , Ogawa Luisa S. , Cai Kathy Q. , Duncan Kelly E. , Duncan James S. , Egleston Brian L. , Proia David A. , Boumber Yanis , Golemis Erica A.
Published: April 2023

Supplemental Materials and Methods and supplemental figure legends
Suppl. Fig 1 from Exosomes in Human Breast Milk Promote EMT
Authors: Qin Wenyi , Tsukasaki Yoshikazu , Dasgupta Santanu , Mukhopadhyay Nitai , Ikebe Mitsuo , Sauter Edward R.
Published: April 2023

Percent change in E-cadherin expression after treatment.
Supplemental Experimental Procedures, Supplementary Tables 1-3, Supplementary Figures 1-9 from Global Metabolic Profiling Identifies a Pivotal Role of Proline and Hydroxyproline Metabolism in Supporting Hypoxic Response in Hepatocellular Carcinoma
Authors: Tang Ling , Zeng Jun , Geng Pengyu , Fang Chengnan , Wang Yang , Sun Mingju , Wang Changsong , Wang Jiao , Yin Peiyuan , Hu Chunxiu , Guo Lei , Yu Jane , Gao Peng , Li Enyou , Zhuang Zhengping , Xu Guowang , Liu Yang
Published: April 2023

Table S1. Clinical information of enrolled subjects for discovery; Table S2. Clinical information of enrolled hepatic carcinoma subjects for validation; TableS3. Differential metabolites obtained from tissue specimens in metabolomics discovery; Figure S1. Scheme of the metabolic characterization study of hepatic carcinoma; Figure S2. Metabolic pathway analysis for HCC. Figure S3. Refining of important differential metabolites; Figure S4. The correlation between hydroxyproline and clinical parameters for discovery specimens; Figure S5. Proliferation assay in tumor xenografts; Figure S6. mRNA levels of PRODH2 and ALDH18A1 in HCC under hypoxia; Figure S7. 13C5 glutamine tracer analysis for glutamate and proline production under hypoxic condition in SMMC-7721 cell line. (mean± SE); Figure S8. Knockdown of MYC has no effect on expression of prolidase in HCC cell; Figure S9. Knockdown of ALDH18A1 induced apoptosis in the presence of sorafenib under hypoxia.
Supplementary Data File 4 from Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker
Authors: Pietrasz Daniel , Pécuchet Nicolas , Garlan Fanny , Didelot Audrey , Dubreuil Olivier , Doat Solène , Imbert-Bismut Francoise , Karoui Mehdi , Vaillant Jean-Christophe , Taly Valérie , Laurent-Puig Pierre , Bachet Jean-Baptiste
Published: April 2023

Preliminary data of monitoring ctDNA compared to radiological findings during oncological follow-up.
Supplement Figure 3 from A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer
Authors: McKay Rana R. , Werner Lillian , Mostaghel Elahe A. , Lis Rosina , Voznesensky Olga , Zhang Zhenwei , Marck Brett T. , Matsumoto Alvin M. , Domachevsky Liran , Zukotynski Katherine A. , Bhasin Manoj , Bubley Glenn J. , Montgomery Bruce , Kantoff Philip W. , Balk Steven P. , Taplin Mary-Ellen
Published: April 2023

Color figure 3 for supplement.
Figure S2 from Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Authors: Xu Chunxiao , Zhang Yanping , Rolfe P. Alexander , Hernández Vivian M. , Guzman Wilson , Kradjian Giorgio , Marelli Bo , Qin Guozhong , Qi Jin , Wang Hong , Yu Huakui , Tighe Robert , Lo Kin-Ming , English Jessie M. , Radvanyi Laszlo , Lan Yan
Published: April 2023

NHS-muIL12 and avelumab combination treatment changed the immunophenotypic signature in spleen and tumor.
Supplementary table S2 from A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases
Authors: Montfort Anne , Pearce Oliver , Maniati Eleni , Vincent Benjamin G. , Bixby Lisa , Böhm Steffen , Dowe Thomas , Wilkes Edmund H. , Chakravarty Probir , Thompson Richard , Topping Joanne , Cutillas Pedro R. , Lockley Michelle , Serody Jonathan S. , Capasso Melania , Balkwill Frances R.
Published: April 2023

List of antibodies used for flow cytometry analyses of human and mouse tissues.
Supplementary Revised Figure S4 from MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53
Authors: Lakshmanan Imayavaramban , Salfity Shereen , Seshacharyulu Parthasarathy , Rachagani Satyanarayana , Thomas Abigail , Das Srustidhar , Majhi Prabin D. , Nimmakayala Rama Krishna , Vengoji Raghupathy , Lele Subodh M. , Ponnusamy Moorthy P. , Batra Surinder K. , Ganti Apar Kishor
Published: April 2023

Stable knockdown of TSPYL5 in lung cancer cells. A, MUC16 expression was significantly elevated in cisplatin resistant cell line. To determine the TSPYL5 role in lung cancer, we stably knocked down TSPYL5 in H292 cells. B, Upon TSPYL5 knockdown, the expression of p53 was increased as compared to scramble cells. C, Knockdown of TSPYL5 was also confirmed by QPCR analysis. β-actin was used as loading control. **P<0.01.
Supplementary Revised Figure S3 from MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53
Authors: Lakshmanan Imayavaramban , Salfity Shereen , Seshacharyulu Parthasarathy , Rachagani Satyanarayana , Thomas Abigail , Das Srustidhar , Majhi Prabin D. , Nimmakayala Rama Krishna , Vengoji Raghupathy , Lele Subodh M. , Ponnusamy Moorthy P. , Batra Surinder K. , Ganti Apar Kishor
Published: April 2023

Chemoresistance properties of MUC16 and effect of cisplatin on apoptosis of MUC16 knockdown cells. A & B, MUC16 knockdown (H1975-shMUC16 seq1 and 2) cells were highly sensitive to cisplatin (A) and gemcitabine (B). C, The percentage of apoptotic cells was significantly higher in MUC16 knockdown cells (H292-shMUC16) treated with 5μM cisplatin. In contrast, no significant change was observed in the untreated scramble (H292-SCR) and MUC16 knockdown cells. D, We performed stable knockdown of Muc16 in K1418, the result shows that Muc16 is significantly decreased as compared to scramble cells. E, The p53 target gene p21 was significantly increased in MUC16 knockdown (H292-shMUC16) cells. *P<0.05, **P<0.01, ***P<0.001, and NS non-significant.
Supplemental figure 2 from Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum
Authors: Hulbert Alicia , Jusue-Torres Ignacio , Stark Alejandro , Chen Chen , Rodgers Kristen , Lee Beverly , Griffin Candace , Yang Andrew , Huang Peng , Wrangle John , Belinsky Steven A. , Wang Tza-Huei , Yang Stephen C. , Baylin Stephen B. , Brock Malcolm V. , Herman James G.
Published: April 2023

Receiver operator classification curves for lung cancer detection for the genes obtained from sputum
Supplementary Table 1 from A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy
Authors: Sayyid Rashid K. , Evans Andrew , Hersey Karen , Maloni Ranjena , Hurtado-Coll Antonio , Kulkarni Girish , Finelli Antonio , Zlotta Alexandre R. , Hamilton Robert , Gleave Martin , Fleshner Neil E.
Published: April 2023

Safety Data
Supplementary Materials from Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials
Authors: Skates Steven J. , Greene Mark H. , Buys Saundra S. , Mai Phuong L. , Brown Powel , Piedmonte Marion , Rodriguez Gustavo , Schorge John O. , Sherman Mark , Daly Mary B. , Rutherford Thomas , Brewster Wendy R. , O'Malley David M. , Partridge Edward , Boggess John , Drescher Charles W. , Isaacs Claudine , Berchuck Andrew , Domchek Susan , Davidson Susan A. , Edwards Robert , Elg Steven A. , Wakeley Katie , Phillips Kelly-Anne , Armstrong Deborah , Horowitz Ira , Fabian Carol J. , Walker Joan , Sluss Patrick M. , Welch William , Minasian Lori , Horick Nora K. , Kasten Carol H. , Nayfield Susan , Alberts David , Finkelstein Dianne M. , Lu Karen H.
Published: April 2023

Supplementary Materials describing "Inclusion and Exclusion Criteria" for the two studies, a detailed description of the "ROCA methods", "Sample Handling and CA125 Assay Instrumentation", and derivation of standards for "Specificity and Positive Predictive Values" for a cohort of women at increased risk.
Supplementary Table 3 from Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy
Authors: Weiss Glen J. , Beck Julia , Braun Donald P. , Bornemann-Kolatzki Kristen , Barilla Heather , Cubello Rhiannon , Quan Walter , Sangal Ashish , Khemka Vivek , Waypa Jordan , Mitchell William M. , Urnovitz Howard , Schütz Ekkehard
Published: April 2023

Supplementary Table 3
Supplementary information from Essential Role of DNA Methyltransferase 1–mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors
Authors: Min Hye-Young , Lee Su-Chan , Woo Jong Kyu , Jung Hyun Jin , Park Kwan Hee , Jeong Hae Min , Hyun Seung Yeob , Cho Jaebeom , Lee Wooin , Park Ji Eun , Kwon So Jung , Lee Hyo-Jong , Ni Xiao , Shin Young Kee , Johnson Faye M. , Duvic Madeleine , Lee Ho-Young
Published: April 2023

Supplementary Methods Supplementary Table S1. Enhanced phosphorylation of several protein kinases such as IGF-1R and Akt in vorinostat-resistant H1944R compared to its parental control (H1944). Supplementary Table S2. Synergistic effect of combinatorial treatment with erlotinib and linsitinib in H1944R cells. Supplementary Table S3. Primer sequences used for MSP. Supplementary Table S4. Primer sequences used for ChIP analysis. Supplementary Table S5. Primer sequences used for RT-PCR analysis.
Supplementary Figures from Essential Role of DNA Methyltransferase 1–mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors
Authors: Min Hye-Young , Lee Su-Chan , Woo Jong Kyu , Jung Hyun Jin , Park Kwan Hee , Jeong Hae Min , Hyun Seung Yeob , Cho Jaebeom , Lee Wooin , Park Ji Eun , Kwon So Jung , Lee Hyo-Jong , Ni Xiao , Shin Young Kee , Johnson Faye M. , Duvic Madeleine , Lee Ho-Young
Published: April 2023

Supplementary Figure S1. The involvement of the IGF-1R activation in acquired resistance to vorinostat. Supplementary Figure S2. Differential regulation of the CTCF binding to the CTCF6 site in the H19/IGF2 ICR according to vorinostat sensitivity. Supplementary Figure S3. Enhanced apoptosis by combinatorial treatment with vorinostat and Stattic. Supplementary Figure S4. The association of DNMT1 expression with vorinostat sensitivity in lymphoma cell lines.
Supplementary Methods, Supplementary Tables 1-3 from A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
Authors: Juric Dejan , de Bono Johann S. , LoRusso Patricia M. , Nemunaitis John , Heath Elisabeth I. , Kwak Eunice L. , Macarulla Mercadé Teresa , Geuna Elena , Jose de Miguel-Luken Maria , Patel Chirag , Kuida Keisuke , Sankoh Serap , Westin Eric H. , Zohren Fabian , Shou Yaping , Tabernero Josep
Published: April 2023

Table S1. Summary of most common drug-related AEs, by dosing schedule; Table S2. Summary of pharmacokinetic parameters of TAK-117 on day 1 of cycle 1 across different dosing schedules (pharmacokinetics-evaluable population); Table S3. Summary statistics of TAK-117: multiple-dose pharmacokinetic parameters across different schedules (pharmacokinetics-evaluable population).